Skip to content

Rapid Micro Biosystems RPID Warrant to purchase Class A common stock

Warrant to purchase Class A common stock at other companies

GCM Grosvenor Inc. logo
GCM Grosvenor Inc.GCMG
$3.38M
Ispire Technology Inc. logo
Ispire Technology Inc.ISPR
$91.49K
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$2.52M-75.7%
Envoy Medical logo
Envoy MedicalCOCH
$882K+348%
KEE
Keel Infrastructure Corp. Common StockKEEL
$11.48M
Evommune
 logo
Evommune EVMN
$150

Other financials

Income statement

See full
Revenue$8.0M+11.1%
Gross profit$371.0K-8.2%
Operating income-$13.9M-18.8%
Net income-$14.3M-26.7%
EPS (diluted)-$0.31-19.2%

Balance sheet

See full
Cash & equivalents$14.1M-26.8%
Total debt$23.8M+301%
Total equity$20.4M-68.9%
Total assets$62.4M-27.0%

Cash flow

See full
Operating cash flow-$15.1M-66.1%
CapEx$394.0K+23.5%
Free cash flow-$15.5M-64.7%

Valuation

See full
Market cap$86.19M-43.8%
Enterprise value$95.86M-31.7%
P/S2.5×-2.6×

Profitability

See full
Operating margin-144.2%-12.7pp
Net margin-145.8%-5.0pp
FCF margin-110.5%-14.9pp

Returns & leverage

See full
Return on equity-116.7%-620pp
Debt / equity1.2×+1.1×
Current ratio2.6×-2.0×

Where this comes from

Reported directly by Rapid Micro Biosystems in its filing.

Tagged under the XBRL concept rmb:WarrantsIssued.

The official record: Rapid Micro Biosystems’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rapid Micro Biosystems's warrant to purchase class a common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rapid Micro Biosystems's warrant to purchase class a common stock?
Rapid Micro Biosystems (RPID) reported warrant to purchase class a common stock of $79.25K in Q4 2025.
What does warrant to purchase class a common stock mean?
This tracks the issuance of warrants to purchase common stock, often used as a sweetener in financing transactions or as part of compensation structures. It serves as a leading indicator of potential future equity dilution and changes in capital structure. Investors monitor this to assess the long-term impact on earnings per share and shareholder ownership stakes.